Hospitalizations for bleeding associated with apixaban versus rivaroxaban according to dose in Medicare beneficiaries
Introduction: Apixaban and rivaroxaban are the most prescribed direct oral anticoagulants, and the safety of different doses in patients at high risk for bleeding is not fully defined. The objective of this study was to compare the rate of hospitalizations due to bleeding in patients prescribed apix...
Saved in:
| Main Authors: | Luke S. Vest, Seo H. Baik, Fitsum Baye, Kin-Wah Fung, Clement J. McDonald |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | Thrombosis Update |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666572725000239 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
by: Mette Søgaard, et al.
Published: (2019-03-01) -
Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation
by: S. G. Kanorskii
Published: (2016-09-01) -
In Vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments
by: Zihan Liu, et al.
Published: (2025-03-01) -
Safety and efficacy of apixaban in patients with glomerulonephritis and nephrotic syndrome: a prospective longitudinal cohort study
by: I. S. Mykhaloiko, et al.
Published: (2025-03-01) -
Plasma levels of direct Xa inhibitors apixaban and rivaroxaban in patients with venous thromboembolism in clinical practice
by: I. Paskaleva, et al.
Published: (2025-05-01)